Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

To take part in this extended study, you must have already been in the first part of the trial (called Study 20210184) and completed your final visit at 72 weeks. You also must not have stopped taking the study medicine in the earlier trial. Most importantly, you need to be willing to follow all the study rules, including using specific birth control methods if you could become pregnant, for a certain period during and after the study.

There are also some reasons why you wouldn't be able to join. For instance, if you're planning to have surgery or a special procedure for obesity during the study, or if your body mass index (BMI) is very low (under 18.5). You also couldn't take part if you've had certain eye conditions, specific types of cancer that weren't fully treated, or if you've been diagnosed with a rare genetic condition called multiple endocrine neoplasia syndrome type 2, or have a close family member who had a specific type of thyroid cancer.

The research team also needs to make sure you're well enough to take part and can complete all the required visits and assessments. They'll also check your mental health, specifically for any signs of severe low mood or thoughts of self-harm, which would prevent you from joining for your safety.

If you join this study, you'll continue to receive either Maridebart Cafraglutide or a placebo, just like in the first part of the trial. This will involve regular visits to the clinic where the study team will carry out various checks. These checks might include blood tests, measuring your weight, blood pressure, and asking you questions about how you're feeling and any changes you've noticed.

You'll need to use specific birth control methods for the duration of the study and for 16 weeks after your last dose of the study medicine. It's important to attend all scheduled appointments so the researchers can keep track of your health and how the medicine is affecting you. The total length of your participation will depend on the study design, but it is an extension of a long-term trial, meaning it will likely continue for a significant period beyond the initial 72 weeks.